Soligenix Toekomstige groei

Future criteriumcontroles 2/6

De winst van Soligenix zal naar verwachting dalen met 12.1% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 44.2% per jaar. De winst per aandeel zal naar verwachting groeien met 44.4% per jaar.

Belangrijke informatie

-12.1%

Groei van de winst

44.4%

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	44.2%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	11 Nov 2024

Recente toekomstige groei-updates

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16

Winst- en omzetgroeiprognoses

NasdaqCM:SNGX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	1	-9	N/A	N/A	2
12/31/2025	1	-9	N/A	N/A	2
12/31/2024	0	-7	N/A	N/A	1
9/30/2024	0	-7	-8	-8	N/A
6/30/2024	0	-7	-8	-8	N/A
3/31/2024	1	-7	-8	-8	N/A
12/31/2023	1	-6	-9	-9	N/A
9/30/2023	1	-8	-10	-10	N/A
6/30/2023	1	-10	-11	-11	N/A
3/31/2023	1	-10	-12	-12	N/A
12/31/2022	1	-14	-13	-13	N/A
9/30/2022	1	-15	-12	-12	N/A
6/30/2022	1	-15	-12	-12	N/A
3/31/2022	1	-15	-11	-11	N/A
12/31/2021	1	-13	-12	-12	N/A
9/30/2021	1	-13	-13	-13	N/A
6/30/2021	1	-12	-13	-13	N/A
3/31/2021	2	-12	-13	-13	N/A
12/31/2020	2	-18	-11	-11	N/A
9/30/2020	3	-15	-10	-10	N/A
6/30/2020	3	-16	-9	-9	N/A
3/31/2020	4	-15	-8	-8	N/A
12/31/2019	5	-9	-8	-8	N/A
9/30/2019	5	-10	-8	-8	N/A
6/30/2019	5	-9	-6	-6	N/A
3/31/2019	5	-8	-8	-8	N/A
12/31/2018	5	-9	-7	-7	N/A
9/30/2018	6	-8	-7	-7	N/A
6/30/2018	6	-7	N/A	-7	N/A
3/31/2018	5	-8	N/A	-6	N/A
12/31/2017	5	-7	N/A	-7	N/A
9/30/2017	6	-5	N/A	-6	N/A
6/30/2017	7	-6	N/A	-6	N/A
3/31/2017	9	-4	N/A	-6	N/A
12/31/2016	10	-3	N/A	-5	N/A
9/30/2016	12	-5	N/A	-5	N/A
6/30/2016	13	-1	N/A	-4	N/A
3/31/2016	11	-4	N/A	-5	N/A
12/31/2015	9	-8	N/A	-5	N/A
9/30/2015	8	-4	N/A	-4	N/A
6/30/2015	7	-11	N/A	-5	N/A
3/31/2015	7	-8	N/A	-4	N/A
12/31/2014	7	-7	N/A	-2	N/A
9/30/2014	6	-8	N/A	-3	N/A
6/30/2014	4	-10	N/A	-4	N/A
3/31/2014	3	-12	N/A	-4	N/A
12/31/2013	3	-10	N/A	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat SNGX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat SNGX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat SNGX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van SNGX ( 44.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van SNGX ( 44.2% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van SNGX naar verwachting over 3 jaar hoog zal zijn

Soligenix Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 13% to US$35.00

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 29% to US$2.50

Consensus EPS estimates upgraded to US$0.63 loss

Price target increased by 7.7% to US$3.50

Recent updates

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 13% to US$35.00

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 29% to US$2.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Consensus EPS estimates upgraded to US$0.63 loss

Price target increased by 7.7% to US$3.50

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Consensus revenue estimates decrease by 11%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

New major risk - Share price stability

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Consensus EPS estimates upgraded to US$0.83 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 35% to US$3.25

Insufficient new directors

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Consensus revenue estimates increase by 13%

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

No longer forecast to breakeven

Consensus revenue estimates decrease by 76%, EPS upgraded

No longer forecast to breakeven

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, SERB Pharma team up to develop therapy for ricin poisoning

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

Price target decreased to US$3.88

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind